Novavax Overview

  • Year Founded
  • 1987

Year Founded

  • Status
  • Public

  • Employees
  • 1,992

Employees

  • Stock Symbol
  • NVAX

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $8.19
  • (As of Friday Closing)

Novavax General Information

Description

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 21 Firstfield Road
  • Gaithersburg, MD 20878
  • United States
+1 (240)
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 21 Firstfield Road
  • Gaithersburg, MD 20878
  • United States
+1 (240)

Novavax Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novavax Stock Performance

As of 14-Feb-2025, Novavax’s stock price is $8.19. Its current market cap is $1.31B with 160M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.19 $8.18 $3.81 - $23.86 $1.31B 160M 4.03M -$2.18

Novavax Financials Summary

As of 30-Sep-2024, Novavax has a trailing 12-month revenue of $847M.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 1,205,634 141,200 41,377 9,307,338
Revenue 847,250 556,382 1,598,951 197,581
EBITDA (216,355) (487,390) (604,713) (1,680,748)
Net Income (284,858) (545,062) (657,939) (1,743,751)
Total Assets 1,712,483 1,797,490 2,258,679 2,576,753
Total Debt 233,308 229,081 549,781 453,991
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Novavax Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Novavax‘s full profile, request access.

Request a free trial

Novavax Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development wi
Biotechnology
Gaithersburg, MD
1,992 As of 2022

Emeryville, CA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Novavax Competitors (51)

One of Novavax’s 51 competitors is Dynavax Technologies, a Formerly VC-backed company based in Emeryville, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dynavax Technologies Formerly VC-backed Emeryville, CA
Moderna Formerly VC-backed Cambridge, MA
CureVac Formerly VC-backed Tubingen, Germany
Valneva Formerly VC-backed Saint-Herblain, France
Cytodyn Formerly Angel backed Vancouver, WA
You’re viewing 5 of 51 competitors. Get the full list »

Novavax Patents

Novavax Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240374712-A1 Sars-cov-2 vaccine compositions Pending 24-Apr-2023
US-20240325523-A1 Coronavirus and influenza compositions and methods for using them Pending 03-Apr-2023
US-20240076320-A1 Downstream process for purification of viral proteins with hydrophobic membrane domain for use in vaccine compositions Pending 01-Sep-2022
AU-2023315949-A1 Pseudovirus based neutralization assay for evaluating vaccine immunogenicity Pending 26-Jul-2022
AU-2023314769-A1 Ace2 inhibition assay for evaluation of vaccine immunogenicity Pending 26-Jul-2022
To view Novavax’s complete patent history, request access »

Novavax Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novavax Investments & Acquisitions (3)

Novavax’s most recent deal was a Merger/Acquisition with Novavax CZ for . The deal was made on 27-May-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Novavax CZ 27-May-2020 Merger/Acquisition Biotechnology
Novavax (Maryland) 22-Aug-2013 Merger/Acquisition Pharmaceuticals
CPL Biologicals 01-Jan-2009 Joint Venture Biotechnology
To view Novavax’s complete investments and acquisitions history, request access »

Novavax ESG

Risk Overview

Risk Rating

Updated March, 19, 2024

27.15 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,120

Rank

Percentile

Pharmaceuticals

Industry

of 853

Rank

Percentile

Biotechnology

Subindustry

of 368

Rank

Percentile

To view Novavax’s complete esg history, request access »

Novavax Exits (1)

Novavax’s most recent exit was on 27-May-2020 from Novavax CZ. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Novavax CZ 27-May-2020 Completed
To view Novavax’s complete exits history, request access »

Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Novavax (150,000-Square Foot Manufacturing Site in Bohumil, Czech Republic) Bohumil, Czech Republic

Novavax FAQs

  • When was Novavax founded?

    Novavax was founded in 1987.

  • Where is Novavax headquartered?

    Novavax is headquartered in Gaithersburg, MD.

  • What is the size of Novavax?

    Novavax has 1,992 total employees.

  • What industry is Novavax in?

    Novavax’s primary industry is Biotechnology.

  • Is Novavax a private or public company?

    Novavax is a Public company.

  • What is Novavax’s stock symbol?

    The ticker symbol for Novavax is NVAX.

  • What is the current stock price of Novavax?

    As of 14-Feb-2025 the stock price of Novavax is $8.19.

  • What is the current market cap of Novavax?

    The current market capitalization of Novavax is $1.31B.

  • What is Novavax’s current revenue?

    The trailing twelve month revenue for Novavax is $847M.

  • Who are Novavax’s competitors?

    Dynavax Technologies, Moderna, CureVac, Valneva, and Cytodyn are some of the 51 competitors of Novavax.

  • What is Novavax’s annual earnings per share (EPS)?

    Novavax’s EPS for 12 months was -$2.18.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »